Intec Pharma to Participate at Four Investment Conferences in March

Thursday, February 28, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

JERUSALEM, Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces

that Company management will participate at the following upcoming investment conferences in March. 

Cowen 39th Annual Health Care ConferenceDate: March 11-13, 2019Company Presentation: Monday, March

11, 2019 at 2:10 pm (Eastern time)

Location: Boston Marriott Copley Place, Boston, MAPresenter: Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec PharmaFormat: Corporate presentation and One-on-One Investor Meetings

Barclays Global Healthcare ConferenceDate: March 12-14, 2019Company Presentation:  March 14, 2019 at 3:05 pm (Eastern time)Location: Loew's South Beach Hotel, Miami, FLPresenter: Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec PharmaFormat: Corporate presentation and One-on-One Investor Meetings

31st Annual ROTH ConferenceDate: March 17-19, 2019 Location: The Ritz Carlton Laguna Nigel, Dana Point, CAPresenter: Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec PharmaFormat: One-on-One Investor Meetings

Oppenheimer's 29th Annual Healthcare ConferenceDate: March 19-20, 2019Company Presentation:  March 20, 2019 at 10:55 am (Eastern time)Location: Westin New York Grand Central, New York City, NYPresenter: Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec PharmaFormat: Corporate presentation and One-on-One Investor Meetings

Mr. Meckler's presentations will be webcast live and will be accessible through the Events section of Intec Pharma's website at, where they will also be archived for a period of time.

About Intec Pharma Ltd. 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in late-stage Phase 3 development for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain indications.

For more information, visit We routinely post information that may be important to investors in the Investor Relations section of our website.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: our limited operating history and history of operating losses, our ability to continue as a going concern, our ability to obtain additional financing, our ability to successfully operate our business or execute our business plan, the timing and cost of our clinical trials, the completion and receiving favorable results in our clinical trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to protect and maintain our intellectual property and licensing arrangements, our ability to develop, manufacture and commercialize our product candidates, the risk of product liability claims, the availability of reimbursement, and the influence of extensive and costly government regulation. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in our most recent Annual Report on Form 10-K filed with the SEC on February 27, 2019, and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Intec Pharma Investor Contact:

Anne Marie Fields                            VP-Corporate Communications & Investor Relations+1-646-200-8808                                 

Cision View original content:

SOURCE Intec Pharma Ltd.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store